Dr. Peter Hamley, Chief Scientific Officer at Samsara Therapeutics, explores whether developments in therapeutics for neurodegenerative diseases are truly disease modifying or addressing the symptoms of a deeper problem.
Dr Robin Knight, Co-Founder & Co-CEO of IN-PART, discusses the emerging importance of outsourcing landscaping activities within the pharmaceuticals industry and the benefits of adopting an openly innovative approach that pools sources of innovation.
Bayer AG hosted its Pharmaceuticals R&D Event 2023 for Investors yesterday. The company presented a deep dive on the innovation strategy in its four therapeutic core areas Oncology, Cardiovascular Diseases, Neurology & Rare Diseases and Immunology.
Dr. Cathy Tralau-Stewart, chief scientific officer at ValiRx, describes the evolution of target validation in drug discovery, ways of tackling project attrition, and the role of human organoid models in future drug discovery strategies.
Neil Thomas, partner and head of health care and life sciences for EMEA at Infosys Consulting, discusses the three tech-enabled R&D opportunities to drive cost-effective transformation that are still missing in the life sciences industry.
Editor, Rebekah Jordan, sat with Mark Bagnall, CEO of Phenomix Sciences, to understand how the company is redefining the way obesity disease is treated with precision medicine to allow for better treatment decisions and patient outcomes.
Dr. Carmen Guguta, Technobis Crystallization Systems, explores how laboratories can do more complex experiments with small amounts of material by using benchtop analytical technology.
Dr. Carmen Guguta, Technobis Crystallization Systems, describes the time-consuming challenges of current crystallisation process, and how innovative analytical instruments are reducing the time it takes to develop drugs to market-ready status.
EPM's Q&A with Jack Dix, head of healthcare strategy and consulting at Kainos, examines technology in genomics research and how cloud data transformation can help to build better patient outcomes.
